Literature DB >> 33973298

An assessment of the analytical performance of non-invasive prenatal testing (NIPT) in detecting sex chromosome aneuploidies: 34,717-patient sample in a single prenatal diagnosis Centre in China.

Yanmei Luo1, Huamei Hu1, Rong Zhang1, Yongyi Ma1, Yan Pan1, Yang Long1, Bin Hu1, Hong Yao2, Zhiqing Liang1.   

Abstract

OBJECTIVE: The present study aimed to evaluate the efficacy of a non-invasive prenatal test (NIPT) in the detection of the sex chromosome aneuploidies (SCAs) at our prenatal diagnosis centre.
METHODS: Among a cohort of 34,717 pregnancies, maternal plasma samples from our prenatal diagnosis centre were subject to analysis of SCAs using NIPT detection. Pregnant women with NIPT positive results of SCAs were recommended to undergo an invasive prenatal diagnosis (i.e. karyotyping and fluorescence in situ hybridization) to validate the prediction value of NIPT.
RESULTS: From 34,717 clinical pregnancies, 229 (0.66%) pregnancies were identified with SCAs. Of these, 78 (34.1%) cases were positive for 45,X and 151 (65.9%) cases comprised a sex chromosome trisomy. Of the 229 positive NIPT results, 193 (84.3%) cases had accepted an invasive diagnosis involving karyotyping analysis of the amniotic fluid, which confirmed 67 cases (34.7%) as true positive, as well as 126 cases (65.3%) as false positive. The positive predictive values were 23.07%, 50%, 36% and 27.27% respectively. The remaining 36 (15.7%) cases declined a prenatal diagnosis. The termination rates of 45,X, 47,XXY, 47,XXX and 47,XYY were 20.5%,46%,12.9% and 11.5% respectively.
CONCLUSIONS: NIPT demonstrated a lower accuracy in predicting monosomy X than sex chromosome trisomies. After invasive testing, the fetal chromosome with 45,X and 47,XXY were terminated more often than those with 47,XXX, 47,XYY. Because NIPT is a screening test, false positive/negative cases exist, and pre- and post-test counselling is essential for informing patients about the benefits and limitations of the test. Confirmatory testing of abnormal results is recommended prenatally or after birth, and the importance of confirmatory testing and benefits of early diagnosis should be addressed.
© 2021 John Wiley & Sons, Ltd.

Entities:  

Keywords:  clinical application value; non-invasive prenatal testing; sex chromosome aneuploidy

Mesh:

Year:  2021        PMID: 33973298     DOI: 10.1002/jgm.3362

Source DB:  PubMed          Journal:  J Gene Med        ISSN: 1099-498X            Impact factor:   4.565


  3 in total

1.  Clinical Application of Noninvasive Prenatal Testing for Sex Chromosome Aneuploidies in Central China.

Authors:  Ganye Zhao; Peng Dai; Conghui Wang; Lina Liu; Xuechao Zhao; Xiangdong Kong
Journal:  Front Med (Lausanne)       Date:  2022-01-26

2.  Systematic analysis of the causes of NIPS sex chromosome aneuploidy false-positive results.

Authors:  Zhaoru Lyu; Chunhong Huang
Journal:  Mol Genet Genomic Med       Date:  2022-05-10       Impact factor: 2.473

3.  A Critical Evaluation of Validation and Clinical Experience Studies in Non-Invasive Prenatal Testing for Trisomies 21, 18, and 13 and Monosomy X.

Authors:  Zachary Demko; Brittany Prigmore; Peter Benn
Journal:  J Clin Med       Date:  2022-08-15       Impact factor: 4.964

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.